A citation-based method for searching scientific literature

Mitsuya Ishikawa, Taro Shibata, Takashi Iwata, Shin Nishio, Toshio Takada, Shiro Suzuki, Koji Horie, Wataru Kudaka, Masahiro Kagabu, Michihiro Tanikawa, Ryo Kitagawa, Munetaka Takekuma, Hiroaki Kobayashi, Nobuo Yaegashi. Gynecol Oncol 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


VEGF-A and the induction of pathological angiogenesis.
Janice A Nagy, Ann M Dvorak, Harold F Dvorak. Annu Rev Pathol 2007
253
100

A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
Tracey E Schefter, Kathryn Winter, Janice S Kwon, Kelly Stuhr, Khalid Balaraj, Brian P Yaremko, William Small, David K Gaffney. Int J Radiat Oncol Biol Phys 2012
60
100



Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Anna Dorothea Wagner, Christoph Thomssen, Johannes Haerting, Susanne Unverzagt. Cochrane Database Syst Rev 2012
42
100

Angiogenesis-inhibitors for metastatic thyroid cancer.
Aihua Tan, Ning Xia, Feng Gao, Zengnan Mo, Yunfei Cao. Cochrane Database Syst Rev 2010
10
100

Microvessel density and distribution in ductal carcinoma in situ of the breast.
A J Guidi, L Fischer, J R Harris, S J Schnitt. J Natl Cancer Inst 1994
229
100

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Krishnansu S Tewari, Michael W Sill, Richard T Penson, Helen Huang, Lois M Ramondetta, Lisa M Landrum, Ana Oaknin, Thomas J Reid, Mario M Leitao, Helen E Michael,[...]. Lancet 2017
175
100


Angiogenesis in cervical intraepithelial neoplasia and the risk of recurrence.
W Tjalma, H Sonnemans, J Weyler, E Van Marck, A Van Daele, P van Dam. Am J Obstet Gynecol 1999
18
100

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Bradley J Monk, Michael W Sill, Robert A Burger, Heidi J Gray, Thomas E Buekers, Lynda D Roman. J Clin Oncol 2009
202
100

Antiangiogenic therapy in oncology: current status and future directions.
Gordon C Jayson, Robert Kerbel, Lee M Ellis, Adrian L Harris. Lancet 2016
405
100

A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
Lindsey E Minion, Jiaru Bai, Bradley J Monk, L Robin Keller, Eskander N Ramez, Gareth K Forde, John K Chan, Krishnansu S Tewari. Gynecol Oncol 2015
35
100

Cervical cancer.
Steven E Waggoner. Lancet 2003
617
100

Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.
Michael F Milosevic, Carol A Townsley, Naz Chaudary, Blaise Clarke, Melania Pintilie, Stacy Fan, Rachel Glicksman, Masoom Haider, Sunmo Kim, Helen MacKay,[...]. Int J Radiat Oncol Biol Phys 2016
16
100

Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study.
Leigh G Seamon, James J Java, Bradley J Monk, Richard T Penson, Jubilee Brown, Robert S Mannel, Anna Oaknin, Mario M Leitao, Eric L Eisenhauer, Harry J Long,[...]. Br J Cancer 2018
6
100

Kidney cancer: The next decade.
Samra Turajlic, Charles Swanton, Chris Boshoff. J Exp Med 2018
34
100

Anti-angiogenic therapies for metastatic colorectal cancer.
Anna Dorothea A D W Wagner, Dirk Arnold, Axel A G Grothey, Johannes Haerting, Susanne Unverzagt. Cochrane Database Syst Rev 2009
80
100

Cervical cancer.
Benjamin E Greer, Wui-Jin Koh, Nadeem R Abu-Rustum, Sachin M Apte, Susana M Campos, John Chan, Kathleen R Cho, Larry Copeland, Marta Ann Crispens, Nefertiti Dupont,[...]. J Natl Compr Canc Netw 2010
49
100


The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24.
Elfriede R Greimel, Karin Kuljanic Vlasic, Ann-Charlotte Waldenstrom, Vlatka M Duric, Pernille T Jensen, Susanne Singer, Weichu Chie, Andy Nordin, Vesna Bjelic Radisic, Dariusz Wydra. Cancer 2006
156
100

Antiangiogenic therapy for high-grade glioma.
Mustafa Khasraw, Malaka S Ameratunga, Robin Grant, Helen Wheeler, Nick Pavlakis. Cochrane Database Syst Rev 2014
83
100

Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?
Neil T Phippen, Charles A Leath, Laura J Havrilesky, Jason C Barnett. Gynecol Oncol 2015
16
100

Pelvic exenteration, University of Michigan: 100 patients at 5 years.
G W Morley, M P Hopkins, S M Lindenauer, J A Roberts. Obstet Gynecol 1989
117
100

Palliative interventions for controlling vaginal bleeding in advanced cervical cancer.
George U Eleje, Ahizechukwu C Eke, Gabriel O Igberase, Anthony O Igwegbe, Lydia I Eleje. Cochrane Database Syst Rev 2019
7
100

Molecularly targeted therapies in cervical cancer. A systematic review.
Flora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, Martin Filipits, Rupert Bartsch. Gynecol Oncol 2012
52
100

Assessing and presenting summaries of evidence in Cochrane Reviews.
Miranda W Langendam, Elie A Akl, Philipp Dahm, Paul Glasziou, Gordon Guyatt, Holger J Schünemann. Syst Rev 2013
119
100

Measuring inconsistency in meta-analyses.
Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman. BMJ 2003
100

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
Harry J Long, Brian N Bundy, Edward C Grendys, Jo Ann Benda, D Scott McMeekin, Joel Sorosky, David S Miller, Lynne A Eaton, James V Fiorica. J Clin Oncol 2005
353
100

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Virginia M Rosen, Ines Guerra, Mary McCormack, Angélica Nogueira-Rodrigues, Andre Sasse, Veronica C Munk, Aijing Shang. Int J Gynecol Cancer 2017
29
100

Changing paradigms in the systemic treatment of advanced cervical cancer.
Krista S Pfaendler, Krishnansu S Tewari. Am J Obstet Gynecol 2016
84
100

Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
Lyndsay J Willmott, Bradley J Monk. Expert Rev Anticancer Ther 2009
34
100

Chemotherapy for metastatic and recurrent cervical cancer.
Kate Scatchard, Jennifer L Forrest, Maxine Flubacher, Paul Cornes, Chris Williams. Cochrane Database Syst Rev 2012
37
100

Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.
Cong Zhou, Sarah Taylor, Jonathan Tugwood, Kathryn Simpson, Gordon C Jayson, Paul Symonds, James Paul, Susan Davidson, Karen Carty, Elaine McCartney,[...]. Br J Clin Pharmacol 2019
2
100

Prognostic role of pretreatment thrombocytosis on survival in patients with cervical cancer: a systematic review and meta-analysis.
Weijuan Cao, Xiaomin Yao, Danwei Cen, Yajun Zhi, Ningwei Zhu, Liyong Xu. World J Surg Oncol 2019
5
100

Targeting angiogenesis in advanced cervical cancer.
Ramez N Eskander, Krishnansu S Tewari. Ther Adv Med Oncol 2014
20
100

Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.
Stefania Bellone, Gianluca Frera, Gianpiero Landolfi, Chiara Romani, Elisabetta Bandiera, Germana Tognon, Juan J Roman, Alexander F Burnett, Sergio Pecorelli, Alessandro D Santin. Gynecol Oncol 2007
67
100

Angiogenesis inhibitors for the treatment of ovarian cancer.
Kezia Gaitskell, Igor Martinek, Andrew Bryant, Sean Kehoe, Shibani Nicum, Jo Morrison. Cochrane Database Syst Rev 2011
29
100

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
A H Calvert, D R Newell, L A Gumbrell, S O'Reilly, M Burnell, F E Boxall, Z H Siddik, I R Judson, M E Gore, E Wiltshaw. J Clin Oncol 1989
100

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
100

Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Richard T Penson, Helen Q Huang, Lari B Wenzel, Bradley J Monk, Sharon Stockman, Harry J Long, Lois M Ramondetta, Lisa M Landrum, Ana Oaknin, Thomas J A Reid,[...]. Lancet Oncol 2015
82
100

Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.
Israel Zighelboim, Jason D Wright, Feng Gao, Ashley S Case, L Stewart Massad, David G Mutch, Matthew A Powell, Premal H Thaker, Eric L Eisenhauer, David E Cohn,[...]. Gynecol Oncol 2013
50
100

Primary cervical screening with high risk human papillomavirus testing: observational study.
Matejka Rebolj, Janet Rimmer, Karin Denton, John Tidy, Christopher Mathews, Kay Ellis, John Smith, Chris Evans, Thomas Giles, Viki Frew,[...]. BMJ 2019
61
100

Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia.
S P Dobbs, P W Hewett, I R Johnson, J Carmichael, J C Murray. Br J Cancer 1997
118
100

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
C Marth, F Landoni, S Mahner, M McCormack, A Gonzalez-Martin, N Colombo. Ann Oncol 2017
220
100

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.
K J Kim, B Li, J Winer, M Armanini, N Gillett, H S Phillips, N Ferrara. Nature 1993
100


A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505).
Isamu Saito, Ryo Kitagawa, Haruhiko Fukuda, Taro Shibata, Noriyuki Katsumata, Ikuo Konishi, Hiroyuki Yoshikawa, Toshiharu Kamura. Jpn J Clin Oncol 2010
46
100

RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.
Tracey Schefter, Kathryn Winter, Janice S Kwon, Kelly Stuhr, Khalid Balaraj, Brian Patrick Yaremko, William Small, William Sause, David Gaffney. Int J Radiat Oncol Biol Phys 2014
68
100

Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
Ryo Kitagawa, Noriyuki Katsumata, Taro Shibata, Toshiharu Kamura, Takahiro Kasamatsu, Toru Nakanishi, Sadako Nishimura, Kimio Ushijima, Masashi Takano, Toyomi Satoh,[...]. J Clin Oncol 2015
158
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.